Edna Danon

Title: **Innovative Contributions of Edna Danon in Pharmaceutical Chemistry**

Introduction

Edna Danon, an accomplished inventor residing in Meitar, Israel, has made significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of four patents, her work focuses on developing processes for synthesizing important pharmaceutical compounds, including Temozolomide and Imatinib. Her innovative approaches have the potential to enhance the efficacy and purity of these vital medications.

Latest Patents

Among Edna Danon's latest inventions is a patented process for preparing highly pure Temozolomide base. This innovative method involves recovery from purification mother liquors using an anionic exchange resin. By treating Temozolomide hydrochloride with an organic acid, a water-miscible organic solvent, and water, Edna successfully obtains Temozolomide free base in an acidic medium. This process is especially advantageous due to the high sensitivity of Temozolomide to basic pH values, allowing for the recovery of high yields of pure Temozolomide base in controlled acidic conditions.

Additionally, she has developed a process for producing Imatinib and its salts, including Imatinib mesylate. This method entails reacting 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid with a specific nitrogen-containing compound in the presence of a carboxylic acid coupling reagent, resulting in the production of Imatinib, which can then be converted into a salt.

Career Highlights

Edna Danon's career is marked by her potent innovation in pharmaceutical processes, which has gained her recognition in the industry. Her contributions to Chemagis Ltd., where she continues to work, highlight her commitment to advancing pharmaceutical research and development. The impact of her work not only contributes to the scientific community but also supports the manufacturing of essential medications that benefit patients worldwide.

Collaborations

Throughout her career, Edna has collaborated with notable colleagues, including Joseph Kaspi and Olga Etlin. These collaborations have fostered an environment of shared knowledge and innovation, further enhancing the potential applications of their research. The collective expertise within this team has been crucial in driving forward the advances in pharmaceutical solutions.

Conclusion

Edna Danon stands as a prominent figure in the landscape of pharmaceutical innovation. Her patents and collaborative efforts reflect her dedication to developing new processes that improve medication production. As she continues her work at Chemagis Ltd., her contributions are anticipated to make significant impacts on pharmaceutical chemistry and patient care in the years to come.